focus -WSS

focus

author：entertainment 2025-10-02 20:06:14 - browse：65733

Portrait of R. Shawn Martin -- health coverage from STAT — R. Shawn Martin, the CEO of the American Academy of Family Physicians Courtesy American Academy of Family Physicians

In ten years, the United States could be short as many as 48,000 primary care doctors. The specialty is underpaid, to a point that doctors are lobbying Medicare to pay it extra. Even medical residents who chose the specialty are leaving primary care; some 45% of residents who planned to be generalists changed their mind during their residencies.

But R. Shawn Martin, the CEO of the American Academy of Family Physicians, the specialty trade group, isn’t worried.

“I’ve been around this and at this a long time and family medicine and primary care’s obituary has been written many times in my 25-plus years of doing this work,” he said with a laugh. “This isn’t the first time that primary care has been dying or fading away.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： UnitedHealth increases loan offers after Change Healthcare outage

explore

WSS

Plastic surgeons increase patient psychiatric screenings

Asbestos, a deadly carcinogen, banned by EPA

Virtual Event: March of the Biosimilars

Positive childhood experiences can help future health

Stop the failed accountable care organization experiment

Plastic surgeons increase patient psychiatric screenings

hotspot

focus

focus

The high cost of giving birth even with insurance

Leading voice in opioid treatment defends methadone clinic system

Heart attack and stroke risk calculators need revising

Neuroscience’s long legacy of racism

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Baby aspirin cuts fat buildup in liver disease patients, in small study

Jerome Adams on the need for new antivirals for Covid

Future doctors should be trained to promote social change

Medicare details structure of new drug price negotiation program

Orchard's therapy for neuron disease in children wins FDA approval

hotspot

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Health AI adoption puts security, privacy startups on investors' radar

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

AstraZeneca to buy developer of next

focus

explore

hotspot

explore